www.ema.europa.eu EMA’s human medicines committee (CHMP) has recommended revoking the marketing authorisation for Adakveo (crizanlizumab), a medicine for preventing painful crises (called vaso-occlusive crises) in patients aged 16 years and older with sickle cell disease.This follows a...

www.ema.europa.eu CVMP opinions on veterinary medicinal productsUnder Regulation (EU) 2019/6The Committee adopted by consensus a positive opinion for a marketing authorisation application for Eluracat (capromorelin tartrate), from Elanco GmbH, a new product for body weight gain in cats...

www.ema.europa.eu CVMP opinions on veterinary medicinal productsUnder Regulation (EU) 2019/6The Committee adopted by consensus a positive opinion for a marketing authorisation application for Eluracat (capromorelin tartrate), from Elanco GmbH, a new product for body weight gain in cats...

www.ema.europa.eu EMA has published recommendations for industry on good practices to ensure continuity in the supply of human medicines, prevent shortages and reduce their impact .Medicine shortages are a global health problem and are increasingly affecting European countries. Shortages...

www.ema.europa.eu The European Medicines Agency's (EMA) office is closed from 18:30 on Wednesday 17 May until 07:30 on Monday 22 May. Outside of working hours and on public holidays, it is possible to call the product emergency hotline on +31(0)88 781 7600.Please note that this is an...